BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:3351. [PMID: 35884412 DOI: 10.3390/cancers14143351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Espejo-cruz ML, González-rubio S, Espejo JJ, Zamora-olaya JM, Alejandre-altamirano RM, Prieto-torre M, Linares CI, Guerrero-misas M, Barrera-baena P, Poyato-gonzález A, Sánchez-frías M, Ayllón MD, Rodríguez-perálvarez ML, de la Mata M, Ferrín G. Enumeration and Characterization of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. IJMS 2023;24:2558. [DOI: 10.3390/ijms24032558] [Reference Citation Analysis]
2 Filippi L, Bagni O, Notarianni E, Saltarelli A, Ambrogi C, Schillaci O. PET/CT with (18)F-choline or (18)F-FDG in Hepatocellular Carcinoma Submitted to (90)Y-TARE: A Real-World Study. Biomedicines 2022;10. [PMID: 36428565 DOI: 10.3390/biomedicines10112996] [Reference Citation Analysis]
3 Xie Q, Huang L, Gao F, Liu D, Wang X, Jiang K, Gong J, Zhao X, Gao B, Lei Z. Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor. Front Pharmacol 2022;13:965770. [DOI: 10.3389/fphar.2022.965770] [Reference Citation Analysis]